Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Sonnet BioTherapeutics Holdings, Inc. from 31 Dec 2012 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Sonnet BioTherapeutics Holdings, Inc. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Dec 2012 to 30 Sep 2025.
  • Sonnet BioTherapeutics Holdings, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Sep 2025 was $5,523,855, a 77% decline year-over-year.
  • Sonnet BioTherapeutics Holdings, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 30 Sep 2025 was $15,793,087, a 112% decline year-over-year.
  • Sonnet BioTherapeutics Holdings, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2025 was $15,793,087, a 112% decline from 2024.
  • Sonnet BioTherapeutics Holdings, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $7,437,232.
  • Sonnet BioTherapeutics Holdings, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2018 was $7,900,491, a 1.2% decline from 2017.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Sonnet BioTherapeutics Holdings, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $15,793,087 $5,523,855 -$2,395,262 -77% 01 Jul 2025 30 Sep 2025 10-K 16 Dec 2025 2025 FY
Q2 2025 $13,397,825 $3,775,804 -$270,249 -7.7% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q3
Q1 2025 $13,127,576 $3,491,122 -$3,856,547 -1055% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q2
Q4 2024 $9,271,029 $3,002,306 -$1,833,797 -157% 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2025 2024 Q1
Q3 2024 $7,437,232 $3,128,593 01 Jul 2024 30 Sep 2024 10-K 16 Dec 2025 2025 FY
Q2 2024 $3,505,555 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q3
Q1 2024 $365,425 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q2
Q4 2023 $1,168,509 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025 2024 Q1

Sonnet BioTherapeutics Holdings, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $15,793,087 -$8,355,855 -112% 01 Oct 2024 30 Sep 2025 10-K 16 Dec 2025 2025 FY
2024 $7,437,232 01 Oct 2023 30 Sep 2024 10-K 16 Dec 2025 2025 FY
2018 $7,900,491 -$89,827 -1.2% 01 Jan 2018 31 Dec 2018 10-K 01 Apr 2019 2018 FY
2017 $7,810,664 -$3,663,093 -88% 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
2016 $4,147,571 -$12,041,856 -153% 01 Jan 2016 31 Dec 2016 10-K 30 Mar 2018 2017 FY
2015 $7,894,285 +$14,096,659 01 Jan 2015 31 Dec 2015 10-K 31 Mar 2017 2016 FY
2014 $6,202,374 -$915,280 -17% 01 Jan 2014 31 Dec 2014 10-K 31 Mar 2016 2015 FY
2013 $5,287,094 -$2,139,734 -68% 01 Jan 2013 31 Dec 2013 10-K 15 Apr 2015 2014 FY
2012 $3,147,360 01 Jan 2012 31 Dec 2012 10-K 31 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.